United Services Automobile Association Incyte Corp Transaction History

United Services Automobile Association

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 13, 2019	SELL	$72.82 - $86.52 $10.4 Million - $12.3 Million	-142,328 Closed	0 $0
Q2 2019 Aug 16, 2019	BUY	$73.52 - $88.7 $93,885 - $113,269	1,277 Added 0.91%	142,328 $12.1 Million
Q1 2019 May 13, 2019	BUY	$63.56 - $88.17 $177,395 - $246,082	2,791 Added 2.02%	141,051 $12.1 Million
Q4 2018 Feb 13, 2019	BUY	$58.5 - $69.94 $113,314 - $135,473	1,937 Added 1.42%	138,260 $8.79 Million
Q3 2018 Nov 13, 2018	BUY	$61.75 - $74.23 $89,414 - $107,485	1,448 Added 1.07%	136,323 $9.42 Million
Q2 2018 Sep 27, 2018	BUY	$60.85 - $83.98 $1.59 Million - $2.19 Million	26,119 Added 24.02%	134,875 $9.04 Million
Q2 2018 Aug 10, 2018	SELL	$60.85 - $83.98 $1.61 Million - $2.23 Million	-26,539 Reduced 19.62%	108,756 $581,000
Q1 2018 May 14, 2018	BUY	$83.06 - $100.98 $92,944 - $112,996	1,119 Added 0.83%	135,295 $11.3 Million
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $509,902 - $635,470	5,450 Added 4.23%	134,176 $12.7 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $14.1 Million - $17.8 Million	128,726	128,726 $15 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of United Services Automobile Association, based on Form 13F filings with the SEC.

Stay updated on United Services Automobile Association with notifications on news.